Storys zum Thema Medizin, Gesundheit

ZENTIVA Pharma GmbH

Zentiva Reinforces Its Presence In Greece To Better Serve Greek People

Prague (ots/PRNewswire) - Zentiva reinforces its presence in Greece by signing a partnership with the company Lavipharm for representation, promotion, and distribution of its pharmaceutical products in Greece. With an established presence in Europe, Zentiva continues to strengthen its capabilities and service offering for people, by partnering with Lavipharm. "We are ...

Servier

Galapagos and Servier report topline results for ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients

Mechelen, Belgium and Paris (ots/PRNewswire) - Servier and Galapagos NV report that no signal of activity was observed in the topline results in their ROCCELLA Phase 2 trial with GLPG1972/S201086. ROCCELLA is a global, double-blind, placebo-controlled, dose ranging trial evaluating the efficacy and safety of three ...

International Center for Journalists (ICFJ); Tow Center for Digital Journalism at Columbia University

New Global Survey Raises Red Flags for Journalism in the COVID-19 Era

London (ots/PRNewswire) - Results launched today by International Center for Journalists (ICFJ) and Tow Center for Digital Journalism at Columbia University Facing everything from a barrage of disinformation to heightened security risks and a mental health crisis, journalists around the world are contending with myriad daunting challenges as they report on a deadly pandemic, according to the first results from a global ...

ZENTIVA Pharma GmbH

Meet Zent2U at Virtual CPhi Festival of Pharma 2020

Prague (ots/PRNewswire) - The B2B Zent2U platform, powered by Zentiva, attends the online CPhI Festival of Pharma. The team will showcase its R&D pipeline assets for strategic partnerships through Zent2u. During this virtual congress, Zent2U representatives will meet with strategic stakeholders to discuss future collaboration leading to partnerships for success. "Building win-win partnerships is at the heart of our growth ...

Oxford Nanopore Technologies

LamPORE test for SARS-CoV-2 detection gains CE-IVD mark

Oxford, England (ots/PRNewswire) - LamPORE is a new, rapid, scalable, accurate test, for the detection of the SARS-CoV-2 virus that causes COVID-19. LamPORE is designed to be performed on a desktop device, GridION, or a palm-sized device, MinION Mk1C. Following an application to the UK's MHRA, the LamPORE assay is now CE marked for in vitro diagnostic use for the detection of the SARS-CoV-2 virus, using the GridION ...

Servier

Amgen, Cytokinetics And Servier Announce Topline Results From GALACTIC-HF, A Phase 3 Trial Of Omecamtiv Mecarbil In Patients With Heart Failure

Thousand Oaks, Calif., South San Francisco, Calif., and Suresnes, France (ots/PRNewswire) - - Trial Met Primary Composite Endpoint of Reduction in Cardiovascular Death or Heart Failure Events - Trial Did Not Meet Secondary Endpoint of Reduction in Cardiovascular Death - Results Will Be Presented in Late Breaking ...

HARMONY Alliance

The HARMONY Alliance launches HARMONY PLUS, a new public-private partnership to improve outcomes for patients with blood cancers

The Hague, Netherlands (ots/PRNewswire) - - HARMONY PLUS builds upon the success of HARMONY in capitalizing on Big Data to speed up the development of more effective treatments for patients with blood cancers. - HARMONY PLUS will leverage the HARMONY Big Data Platform, a central data poolof anonymized data, ...

Merck Healthcare Germany

Merck Announces Out-Licensing Agreement for Phase II-ready Anti-ADAMTS5 Nanobody for Osteoarthritis

Darmstadt, Germany (ots/PRNewswire) - - Merck out-licenses promising clinical-stage program to Novartis - Anti-ADAMTS5 Nanobody® programis Phase II-ready with novel MoA which could protect against cartilage damage and reduce joint pain - Merck receives upfront payment of EUR 50 million with the potential of ...

Debiopharm International SA

Debiopharm and the Japanese Cancer Association Announce Winners of the 2020 JCA-Mauvernay Award

Lausanne (ots) - For its sixteenth edition, the JCA-Mauvernay Award was awarded to Doctor Hideaki Ogiwara and Doctor Keisuke Kataoka Debiopharm (www.debiopharm.com), a Swiss-based global, biopharmaceutical company, presented the JCA-Mauvernay Award on October 3rd to Dr. Hideaki Ogiwara from the Division of Cancer Therapeutics of the National Cancer Center Research ...

Debiopharm International SA

DEBIOPHARM LAUNCHES TRILYNX - A LARGE-SCALE PHASE III CLINICAL TRIAL TO FURTHER EVALUATE XEVINAPANT IN THE TREATMENT OF HEAD & NECK CANCER

Lausanne, Switzerland (ots) - First patient dosed in the randomized, placebo-controlled Phase III study of xevinapant (Debio 1143) vs placebo when added to chemoradiotherapy (CRT) in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) Debiopharm (www.debiopharm.com), a ...

Sophia Genetics

SOPHiA GENETICS Raises $110 Million in Oversubscribed New Funding Round

Lausanne, Switzerland and Boston (ots/PRNewswire) - Supporting the Company's Global Expansion to Meet Growing Clinical and Biopharma Demand for Data-Driven Medicine - SOPHiA GENETICS enters next stage of its global expansion with oversubscribed Series F round exceeding $110 million, led by major health-tech fund and followed by strategic industry leader - Company ...

Medasense Biometrics Ltd

New Study: Postoperative Pain Can Be Reduced by Using NOL Monitoring to Guide Analgesic Medication During Surgery

Ramat Gan, Israel (ots/PRNewswire) - A new study has found that monitoring pain response levels during surgery with NOL technology (Medasense, Ramat Gan, Israel) can help reduce postoperative pain. Exploring the potential use of NOL monitoring to help enhance recovery after surgery, the study demonstrated that ...

BioVisioN

Biovision Foundation / A decade on: A critical new book by UN's World Agriculture Report (IAASTD) members calls for an accelerated transformation of our food systems

Zurich (ots/PRNewswire) - It is perfect timing: In mid-October the world will discuss the topic. A ground breaking book has been published today to support governments, NGOs and the wider public as they make vital choices that impact the future direction of food production across the globe. The book "Transformation ...

Biovision Stiftung für ökologische Entwicklung

2

Biovision Foundation / A decade on: a critical new book by UN's World Agriculture Report (IAASTD) members calls for an accelerated transformation of our food systems. It is perfect timing: in mid-October the world will discuss the topic

Hovione

Hovione Announces Partnership to Support Manufacturing of Antiviral Veklury® for COVID-19

Lisbon, Portugal (ots/PRNewswire) - Hovione today announced the signing of a partnership agreement with Ligand to significantly ramp up the production output of Captisol®. Captisol®, a Ligand product, is a chemically modified cyclodextrin proven to improve the solubility and stability of drugs. It is used in the formulation of Gilead's COVID-19 treatment Veklury® ...

FDI World Dental Federation

FDI World Dental Federation and Smile Train: Children with clefts are at high risk for tooth decay, gum disease and other serious oral health concerns

Jennewein Biotechnologie GmbH

Jennewein Biotechnologie GmbH and Chr. Hansen A/S to join forces in high-growth Human Milk Oligosaccharides market

Rheinbreitbach and Bonn, Germany (ots/PRNewswire) - Jennewein Biotechnologie GmbH agreed to join forces with Chr. Hansen Holding A/S, a leading bioscience company based in Hoersholm/Denmark, to lead the global market for human milk oligosaccharides (HMOs). Chr. Hansen entered into an agreement to acquire all shares ...

Debiopharm International SA

DEBIOPHARM HONORED AS A 2020 SWISS BIOTECH SUCCESS STORY WINNER FOR OUTSTANDING ACHIEVEMENTS OVER 40 YEARS

Lausanne, Switzerland (ots) - Debiopharm, (www.debiopharm.com), a Swiss-based biopharmaceutical company today announced being one of the recipients of the 2020 Swiss Biotech Success Story Award for exceptional achievements in the biotech industry. Every year, the Swiss Biotech Association awards companies or ...

Debiopharm International SA

DEBIOPHARM TO PRESENT LATE BREAKING HEAD & NECK CANCER ABSTRACT AT THE 2020 EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS

Lausanne, Switzerland (ots) - Debiopharm announces the presentation of the 3-year phase II follow-up data along with 2 posters for xevinapant (antagonist of IAP -Inhibitor of Apoptosis Proteins) and WEE1 inhibitor Debio 0123 Debiopharm, ...

Merck Healthcare Germany

Merck Advances Oncology Portfolio and Pipeline with New and Long-term Data in Multiple Cancers at ESMO 2020

Darmstadt, Germany (ots/PRNewswire) - · New analyses from Phase III JAVELIN Bladder 100 study of BAVENCIO®* assess efficacy across subgroups, patient-reported outcomes and exploratory biomarkers in advanced urothelial cancer · Overall efficacy data, and analyses of brain metastases and HRQoL for tepotinib? from ...

Merck Healthcare Germany

New MAVENCLAD® Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting Highlight Rapid Onset of Action and Compelling Post-Approval Safety

Darmstadt, Germany (ots/PRNewswire) - In MAGNIFY-MS, patients experienced a rapid onset of action from end of Month 1 that was significant in all study periods versus baseline Post-approval safety analysis showed no increased risk of viral respiratory infections and lower rates of malignancy than in the clinical ...

Theratechnologies Inc.

Theratechnologies Announces Launch of Trogarzo® in Germany

Montreal (ots/PRNewswire) - First commercial launch in Europe Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that Trogarzo® will be commercially available in Germany as of tomorrow through its subsidiary, Theratechnologies Europe Limited. Theratechnologies filed its health ...

Merck Healthcare Germany

Merck Announces Positive Phase II Results for Investigational Sonelokinab (M1095) in Patients with Moderate to Severe Chronic Plaque-Type Psoriasis

Darmstadt, Germany (ots/PRNewswire) - Not intended for UK and US based media - Sonelokinab is an investigational IL-17 A/F Nanobody®, which neutralizes both IL-17A and IL-17F - Phase II study was facilitated by Avillion as part of an innovative co-development model Merck, a leading science and technology company, ...

Debiopharm International SA

Belgian scale-up Oncomfort raises EUR10 million in Series A funding co-led by Debiopharm and Crédit Mutuel Innovation to further develop its Digital SedationTM through Virtual Reality